MOUNTAIN VIEW, Calif., March 3 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, Chief Financial Officer, will present an overview of the company at two investment conferences during the month of March.

    The conference presentation schedule is as follows:

     Cowen and Company 30th Annual Health Care Conference
     March 10, 2010 at 9:30 a.m. ET
     The Boston Marriott Copley Place, Boston, MA

     Roth Capital Partners 22nd Annual OC Growth Stock
      Conference
     March 16, 2010 at 12:00 p.m. PT
     The Ritz Carlton, Dana Point, CA

A live audio webcast and 30-day archive of the presentations will be available on VIVUS' website at http://www.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next- generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's lead product in clinical development, Qnexa(R), has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor for the treatment of erectile dysfunction, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

    CONTACT:

    VIVUS, Inc.
    Timothy E. Morris
    Chief Financial Officer
    650-934-5200

    Investor Relations:
    The Trout Group
    Brian Korb
    646-378-2923

    Media Relations:
    Pure Communications, Inc.
    Dan Budwick
    973-271-6085

SOURCE VIVUS, Inc.

Back to top

RELATED LINKS
http://www.vivus.com